A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD
- PMID: 10591283
- DOI: 10.1001/archpsyc.56.12.1073
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD
Abstract
Background: Previous studies have demonstrated the short-term efficacy of pharmacotherapy and behavior therapy for attention-deficit/hyperactivity disorder (ADHD), but no longer-term (i.e., >4 months) investigations have compared these 2 treatments or their combination.
Methods: A group of 579 children with ADHD Combined Type, aged 7 to 9.9 years, were assigned to 14 months of medication management (titration followed by monthly visits); intensive behavioral treatment (parent, school, and child components, with therapist involvement gradually reduced over time); the two combined; or standard community care (treatments by community providers). Outcomes were assessed in multiple domains before and during treatment and at treatment end point (with the combined treatment and medication management groups continuing medication at all assessment points). Data were analyzed through intent-to-treat random-effects regression procedures.
Results: All 4 groups showed sizable reductions in symptoms over time, with significant differences among them in degrees of change. For most ADHD symptoms, children in the combined treatment and medication management groups showed significantly greater improvement than those given intensive behavioral treatment and community care. Combined and medication management treatments did not differ significantly on any direct comparisons, but in several instances (oppositional/aggressive symptoms, internalizing symptoms, teacher-rated social skills, parent-child relations, and reading achievement) combined treatment proved superior to intensive behavioral treatment and/or community care while medication management did not. Study medication strategies were superior to community care treatments, despite the fact that two thirds of community-treated subjects received medication during the study period.
Conclusions: For ADHD symptoms, our carefully crafted medication management was superior to behavioral treatment and to routine community care that included medication. Our combined treatment did not yield significantly greater benefits than medication management for core ADHD symptoms, but may have provided modest advantages for non-ADHD symptom and positive functioning outcomes.
Comment in
-
Development of clinical services for attention-deficit/hyperactivity disorder.Arch Gen Psychiatry. 1999 Dec;56(12):1097-9. doi: 10.1001/archpsyc.56.12.1097. Arch Gen Psychiatry. 1999. PMID: 10591285 No abstract available.
-
MTA Study has flaws.Arch Gen Psychiatry. 2001 Dec;58(12):1184; author reply 1185-7. doi: 10.1001/archpsyc.58.12.1184. Arch Gen Psychiatry. 2001. PMID: 11735849 No abstract available.
-
MTA findings fail to consider methodological issues.Arch Gen Psychiatry. 2001 Dec;58(12):1184-7. doi: 10.1001/archpsyc.58.12.1184-a. Arch Gen Psychiatry. 2001. PMID: 11735850 No abstract available.
Similar articles
-
Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder.Arch Gen Psychiatry. 1999 Dec;56(12):1088-96. doi: 10.1001/archpsyc.56.12.1088. Arch Gen Psychiatry. 1999. PMID: 10591284 Clinical Trial.
-
Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers.J Dev Behav Pediatr. 2001 Feb;22(1):60-73. doi: 10.1097/00004703-200102000-00008. J Dev Behav Pediatr. 2001. PMID: 11265923 Clinical Trial.
-
A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.Pediatrics. 2005 Jan;115(1):e97-104. doi: 10.1542/peds.2004-0953. Pediatrics. 2005. PMID: 15629972
-
Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.Pediatrics. 2005 Jun;115(6):e749-57. doi: 10.1542/peds.2004-2560. Pediatrics. 2005. PMID: 15930203 Review.
-
What does the MTA study tell us about effective psychosocial treatment for ADHD?J Clin Child Psychol. 2001 Mar;30(1):114-21. doi: 10.1207/S15374424JCCP3001_13. J Clin Child Psychol. 2001. PMID: 11294069 Review.
Cited by
-
Rearing in an Enriched Environment Ameliorates the ADHD-like Behaviors of Lister Hooded Rats While Suppressing Neuronal Activities in the Medial Prefrontal Cortex.Cells. 2022 Nov 17;11(22):3649. doi: 10.3390/cells11223649. Cells. 2022. PMID: 36429076 Free PMC article.
-
Current use of attention-deficit hyperactivity disorder (ADHD) medications and clinical characteristics of child and adolescent psychiatric outpatients prescribed multiple ADHD medications in Japan.PLoS One. 2021 Jun 3;16(6):e0252420. doi: 10.1371/journal.pone.0252420. eCollection 2021. PLoS One. 2021. PMID: 34081716 Free PMC article.
-
Switching from Methylphenidate-Immediate Release (MPH-IR) to Methylphenidate-OROS (OROS-MPH): A Multi-center, Open-label Study in Korea.Clin Psychopharmacol Neurosci. 2011 Apr;9(1):29-35. doi: 10.9758/cpn.2011.9.1.29. Epub 2011 Apr 30. Clin Psychopharmacol Neurosci. 2011. PMID: 23430964 Free PMC article.
-
MAGNITIVE: Effectiveness and Feasibility of a Cognitive Training Program Through Magic Tricks for Children With Attention Deficit and Hyperactivity Disorder. A Second Clinical Trial in Community Settings.Front Psychol. 2021 Apr 1;12:649527. doi: 10.3389/fpsyg.2021.649527. eCollection 2021. Front Psychol. 2021. PMID: 33868126 Free PMC article.
-
Methylphenidate use in children with attention deficit hyperactivity disorder.Rev Saude Publica. 2015;49:32. doi: 10.1590/s0034-8910.2015049005966. Epub 2015 Jun 9. Rev Saude Publica. 2015. PMID: 26061456 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical